Drugs / L-LEUCOVORIN
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials | ||||||
| Phase 2 | NCT05062889 | May 2023 → Oct 2027 | malignant colon neoplasm | Gruppo Oncologico del Nord-Ovest | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04513951 | Apr 2020 → Jun 2023 | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Completed | No outcome recorded |
| Phase 2 | NCT03487939 | May 2018 → Oct 2021 | colorectal neoplasm | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03484221 | Apr 2018 → Oct 2021 | rectal neoplasm | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03085992 | Mar 2012 → Jul 2017 | rectal cancer | Azienda Ospedaliero, Universitaria Pisana | Completed | No outcome recorded |
| Phase 2 | NCT01276379 | Jan 2011 → Mar 2017 | colorectal cancer | Grupo Espanol Multidisciplinario del Cancer Digestivo | Completed | No outcome recorded |
| Phase 2 | NCT00209703 | Jan 2005 → Jun 2007 | colorectal cancer | Hokkaido Gastrointestinal Cancer Study Group | Terminated | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00005586 | Oct 1997 → ? | colorectal cancer | Institute of Cancer Research, United Kingdom | Completed | Met primary |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT00631410 Background | Jan 2008 → Jul 2009 | colorectal neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT06219941 Background | Dec 2023 → Aug 2026 overdue | biliary tract cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT03721653 Background | Nov 2018 → Jun 2021 | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Completed | Met primary |
| Phase 2 | NCT03484195 Background | Apr 2018 → Oct 2021 | colonic neoplasm | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT02271464 Background | Mar 2012 → Mar 2017 | colorectal cancer | Azienda Ospedaliero, Universitaria Pisana | Completed | Missed primary |
| Phase 2 | NCT00668863 Background | May 2008 → Sep 2010 | colorectal cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03635021 Background | Oct 2018 → Jun 2025 overdue | colorectal cancer | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03231722 Background | Sep 2017 → Jun 2022 | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Completed | Missed primary |
| Phase 3 | NCT02934464 Comparator | Dec 2016 → Dec 2021 | gastric neoplasm | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Leucovorin | “Phase I Study Of Sunitinib In Combination With Oxaliplatin, L-Leucovorin, And 5-Fluorouracil In Patients With Metastatic Colorectal Cancer” NCT00631410 ↗16“l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.” NCT01276379 ↗ “* FOLFOX4:Oxaliplatin 85 mg/m2. l-Leucovorin 100 mg/m2 5-fluorouracil 400/600 mg/m2.” NCT02934464 ↗ “L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1” NCT03635021 ↗ “L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1” NCT03484221 ↗ “L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1” NCT03487939 ↗ “L-Leucovorin 200 mg/m\^2 IV over 2h, day 1” NCT03484195 ↗ “L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1” NCT03085992 ↗ “L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1” NCT02271464 ↗ |
| Known as | l-LV | “Feasibility Study of mFOLFOX6 (Oxaliplatin Combined With l-Leucovorin (l-LV) and 5-Fluorouracil) in Patients With Advanced Colorectal Cancer” NCT00209703 ↗ |
| Route | Intravenous | “patients receive L-leucovorin IV followed by fluorouracil IV” NCT00005586 ↗ |